The following articles  have been kindly provided by Juan Carlos Baiges

"When you're the first, the whole world's eyes are on you," Advanced Cell Technology's Robert Lanza tells the Washington Post. "We all have our fingers crossed that everything goes smoothly and nothing happens."  

ACT is preparing to ask the FDA for approval to begin a clinical trial of an ESC-based therapy for blindness. And Geron will push ahead with its own trial after recruiting eight to 10 subjects with spinal cord damage.

"Today's news about Geron's embryonic stem cell clinical trials is a milestone in the new era of hope and adds to the momentum for policy change when it comes to embryonic stem cell research," said Amy Comstock Rick of the Coalition for the Advancement of Medical Research.

 
 
 
 

Government Approves Study Using Human Embryonic Stem Cells

By Rob Stein

 

Washington Post Staff Writer 
Saturday, January 24, 2009; Page A06

 

 

A California biotechnology company plans to launch the first government-approved clinical trial testing human embryonic stem cells on people by next summer after receiving federal approval yesterday.

Other researchers had previously begun human testing of embryonic cells derived from adults and fetuses, but the new study will mark the first authorized use of those derived from embryos, which have been highly controversial because the embryos are destroyed in the process.

The Food and Drug Administration approved a request from Geron of Menlo Park to test the stem cells on eight to 10 patients with severe spinal cord injuries. The study, which will be conducted at seven medical centers, is aimed primarily at determining the safety of the cells in human subjects, but researchers also will look for any signs that the therapy restored sensation or movement.

"This is obviously an extraordinarily exciting event," Geron chief executive Thomas B. Okarma said. "It marks the dawn of a new era in medical therapeutics. This approach is one that reaches beyond pills and scalpels to achieve a new level of healing."

President Obama is expected to lift restrictions on federal funding for such research imposed by his predecessor. While the timing of the FDA approval led some to speculate that the two moves were related, Geron's work had not been restricted by the Bush administration policy. The cells being used by the company were derived from leftover embryos at fertility clinics before then-President George W. Bush's 2001 decision. Nevertheless, the FDA's move was welcomed by proponents of lifting the restrictions.

 

"Today's news about Geron's embryonic stem cell clinical trials is a milestone in the new era of hope and adds to the momentum for policy change when it comes to embryonic stem cell research," said Amy Comstock Rick of the Coalition for the Advancement of Medical Research.

Approval of Geron's project had also been eagerly awaited by other stem cell researchers. The FDA had delayed approval of the application in May, asking Geron to provide more information on its plans.

"This is what we've all been waiting for," said Robert Lanza of Advanced Cell Technology in Worcester, Mass., which plans to ask the FDA to approve a study using embryonic stem cells to treat blindness. "The field desperately needs a big clinical success. It's very important to show the naysayers that this is very real, and hopefully it will start helping people."

Lanza, however, expressed concern about the impact of a failure.

"When you're the first, the whole world's eyes are on you," he said. "We all have our fingers crossed that everything goes smoothly and nothing happens."

While stem cells show great promise for treating spinal cord injuries, some researchers wondered whether this was the best first test of the controversial therapy.

"The nervous system would appear to be one of the most challenging and daunting tissues for cell replacement therapy," said Arnold Kriegstein of the University of California at San Francisco. "We have to be prepared for modest benefits and watch carefully for any adverse effects."

The experiment will involve injecting embryonic stem cells that have been coaxed in the laboratory into becoming cells known as oligodendrocytes into the damaged spines of patients seven to 14 days after their injuries. The hope is that the cells will help repair the protective myelin sheath around the nerve cells, restoring the ability of some nerves to carry signals, and perhaps allow damaged cells to regenerate. The patients will receive anti-rejection drugs for 46 days, after which they will be slowly weaned off the medication.

The company submitted a series of laboratory studies and 24 tests involving hundreds of animals that were given a total of more than 5 billion cells. Geron officials said the animals showed no signs of problems such as developing tumors for as much as a year, allaying one concern about using embryonic stem cells.

"This is an exciting first step for Geron and for spinal cord-injured patients whose lives may improve due to advances in medical research," said Peter T. Wilderotter, president and chief executive of the Christopher and Dana Reeve Foundation, in a statement.

While praising the approval, Laurie Zoloth, a bioethicist at Northwestern University, noted that the researchers will be experimenting on an especially desperate group of patients.

"True informed consent in this very vulnerable population, people who have suffered a devastating and life-changing injury a week prior to being asked to enter the first clinical trial for such long-awaited, highly publicized and desperately needed treatment, is hard to obtain and will need to be carefully thought through," she said.

 

 

 January 27, 2009 — 8:39am ET | By John Carroll 

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top